Five Years After Teen Hormone Therapy, Regret Was Rare in a JAMA Pediatrics Cohort
A study published in JAMA Pediatrics found that most transgender and gender-diverse people who began hormone therapy as teenagers said, five years later, that starting treatment was the right decision. The cohort included 376 participants, and 360 of them — nearly 97% — reported no regret at follow-up. Roughly 3% said they regretted taking the medication, and nearly 2% said they both regretted the transition and believed it harmed them.
The findings sit at the center of a debate that often mixes medicine, politics, and identity, but the data themselves are straightforward. Adolescents and young adults who received gender-affirming hormone therapy did not, on the whole, later reverse course. On average, the participants started hormone therapy at age 16, placing the study squarely in the clinical territory where questions about informed assent, family support, mental health, and long-term satisfaction all intersect.
What the Follow-Up Tells Clinicians About Durability of Choice
The core result is not subtle. Five years after treatment began, regret was uncommon. In practical terms, that matters because decisions made in mid-adolescence are often scrutinized for permanence, especially when the intervention involves an enduring change in the body and in social experience. Hormone therapy is not a passing preference; it is a treatment chosen to align physical traits more closely with gender identity, and the durability of that choice is central to how clinicians counsel patients and families.
A 97% affirmation rate does not prove that every patient will experience benefit, and it does not erase the small subset who later have second thoughts. It does show, however, that for most participants in this cohort, the treatment decision held up over time. That is the clinical question that matters at the bedside: whether a teenager who starts hormone therapy is likely to look back years later and still judge the decision as correct.
The Meaning of Regret in Gender-Affirming Care
Regret in this setting is not a single, simple variable. It can reflect dissatisfaction with the treatment itself, discomfort with the transition process, social pressure, or a mismatch between expectations and lived experience. The study separated general regret from the more severe experience of believing the transition caused harm, and the latter group was smaller still. Nearly 2% of participants said both that they regretted the transition and believed it harmed them, a signal that deserves attention even within a largely favorable result.
Hormone therapy works by changing the endocrine environment in ways that can alter secondary sex characteristics over time. For patients whose distress is tied to the sex characteristics they developed at puberty, that mechanism is not cosmetic; it is biologically targeted care aimed at reducing the gap between body and identity. When the treatment fits the patient, the effect can be psychologically stabilizing. When it does not, the consequences can be deeply personal and may persist long after the medication is stopped.
The age of initiation also shapes interpretation. Starting at an average age of 16 means many participants were still adolescents when treatment decisions were made, likely with varying degrees of family involvement and clinical oversight. That context is important because teenage treatment decisions are often portrayed as impulsive. The follow-up data point in the opposite direction for most participants: the initial choice remained acceptable years later.
Why the Numbers Matter Beyond the Culture War
The result should not be used as a slogan, and it should not be overextended beyond the study population. A cohort of 376 people cannot settle every clinical or ethical question about gender-affirming care, especially when individual experiences vary so much. Still, the numbers do address one of the most frequently repeated concerns in this field — that adolescents who start hormone therapy will commonly grow to regret it.
That concern is not supported by the pattern seen here. Instead, the data suggest that regret was the exception, not the norm. For clinicians, that has immediate implications for counseling. It supports a more measured discussion in which the possibility of regret is acknowledged honestly, but not treated as the expected endpoint.
The study also reminds physicians that long-term follow-up is essential. Short-term satisfaction can be misleading if it is not tested against later life experience, and long-term satisfaction can vary depending on mental health, social support, family acceptance, access to ongoing care, and whether treatment goals were clearly discussed before initiation. Those factors are part of the therapeutic context even if they are not the main endpoint.
How the Findings Should Shape Patient Conversations
When adolescents ask about hormone therapy, the conversation often turns quickly to risk. This study gives clinicians a more complete frame. The decision is still serious, still individualized, and still dependent on careful assessment, but the long-term data here suggest that most teens who start treatment do not later wish they had not. In other words, the trajectory for the majority is one of consistency rather than reversal.
That should not eliminate caution. It should refine it. Counseling can acknowledge that a small minority will report regret, that some will feel harmed, and that follow-up must remain active rather than symbolic. At the same time, the evidence from this cohort argues against presenting regret as a common outcome.
In a field where public argument often runs far ahead of the evidence, this study offers a rare clinical anchor: years after starting hormone therapy as teenagers, most participants still judged the decision to be right. The main limitation is built into the size and scope of the cohort, which leaves room for variation outside this sample and does not answer every question about who is most likely to benefit, who is most vulnerable to regret, or how best to tailor follow-up over decades rather than years.